On December 5, MAPS hosted an educational webinar exploring recent research in Alzheimer’s disease (AD) screening, testing, ...

Novartis has announced an agreement with the US government to lower the prices of its medicines in the US and support ...

As part of the three-year agreement, Gilead has agreed to take a series of actions that align with the government’s new drug ...

Novo Nordisk’s Wegovy (semaglutide) pill has been approved by the US FDA as an oral weight loss medication. In addition to ...

Merck (known as MSD outside the US) has announced an agreement with the US government to provide key products to patients at ...

Every year, we’re met with restructuring, hiring freezes, and portfolio cuts. And every year we tell ourselves the same story ...

How was a new rare disease discovered through Singapore’s Undiagnosed Disease Program? And how will technology allow us to change how we discover rare diseases in the future? Read more to find out.

AstraZeneca (AZ) has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for its Imfinzi (durvalumab) regimen in a subset of adults with resectable non ...

VML France has announced the appointment of Philippe Huot-Louradour as director of VML Health France. Huot-Louradour, who has also been appointed as client lead for Sanofi, brings over 25 years of ...

AstraZeneca has reached a deal to buy partner Bristol-Myers Squibb out of their diabetes venture and secure sole rights to key growth drugs such as Onglyza and Forxiga. The deal includes $2.7bn ...

AbbVie will be gaining rights to IGI Therapeutics’ lead candidate for oncology and autoimmune diseases in an exclusive licensing agreement worth over $1.9bn. ISB 2001 is a trispecific T-cell engager ...

ESMO celebrates 50 years of focusing on oncology research; Improving cardiovascular disease therapy; Global pharma pricing impact on supply chains ...